Analyst Ratings February 19, 2026

Benchmark Sticks With Buy on Live Nation Ahead of Quarterly Results

Analysts expect upbeat comments on attendance and international growth even as legal and profitability questions persist

By Ajmal Hussain LYV
Benchmark Sticks With Buy on Live Nation Ahead of Quarterly Results
LYV

Benchmark reiterated a Buy rating and $190 price target on Live Nation Entertainment (LYV) ahead of the company’s earnings release, while legal challenges and a high valuation keep investor attention focused on both growth and risk. InvestingPro data shows the stock trading modestly below its fair value and highlights mixed signals on profitability and regulatory exposure.

Key Points

  • Benchmark reiterated a Buy rating and $190 price target for Live Nation ahead of earnings; stock trading at $155.69 with analyst targets from $135 to $190.
  • Analysts expect management to highlight durable concert attendance and international and Venues growth; company recorded 5.48% revenue growth over the last 12 months.
  • Significant legal exposure remains - SDNY judge allowed the DOJ antitrust case to proceed with trial set to start March 2; allegations include amphitheatre market control and Ticketmaster primary market dominance.

Benchmark has reaffirmed its Buy rating on Live Nation Entertainment (NYSE: LYV) and held a $190 price target ahead of the company's quarterly earnings report scheduled for Thursday. The stock is trading at $155.69, and InvestingPro's fair value assessment indicates it is slightly undervalued relative to analyst targets that span from $135 to $190.

The research house said it expects management to provide constructive commentary during the earnings call on the durability of concert attendance over the long term, as well as continued momentum in international markets and in the Venues segment. Over the most recent 12-month period, Live Nation reported revenue growth of 5.48%, a sign of ongoing top-line traction that Benchmark views as supportive of the Buy stance.

At the same time, Benchmark signaled that company leadership is likely to be cautious in discussing the Department of Justice antitrust matter, despite investors' strong interest in how that legal issue could affect the business. A federal judge in the Southern District of New York, Arun Subramanian, recently ruled that the antitrust suit will proceed and remains scheduled to begin on March 2, with some minor claims dismissed. The allegations continuing include claims that Live Nation leveraged its leading amphitheatre footprint to exert market control and allegations tied to Ticketmaster's primary market dominance.

InvestingPro's analysis rates Live Nation's overall financial health as "GREAT," assigning a score of 3.03, which the data set presents as evidence of solid fundamentals. Nonetheless, the company carries a high price-to-earnings multiple - 112.95 - that reflects a premium valuation. This elevated P/E exists even as InvestingPro's analyst consensus projects a decline in net income for the company this year.

Settlement negotiations between Live Nation and the DOJ remain active, according to reports in financial and music industry outlets. Media coverage referenced within those reports suggests some figures in the Trump Administration may be open to a settlement, while state attorneys general - with California's Rob Bonta cited by name - could present more resistance to any negotiated resolution.

Benchmark also addressed the secondary ticket market in its commentary, saying Ticketmaster is a comparatively marginal participant in that market and thus an unfair singular target for abuses alleged there. The firm noted Live Nation management has publicly supported measures to restrict premiums in the secondary market - a policy stance that intersects with broader debates over pricing power and consumer-facing ticket fees.

Legal pressure has mounted elsewhere: a federal judge rejected Live Nation's attempt to dismiss an antitrust suit brought by the U.S. government and multiple states, which accuses the company of trying to dominate the live events ecosystem and contributing to higher ticket prices. The Justice Department has advocated in court for breaking up Live Nation, asserting that the company penalizes venues that do not use Ticketmaster and that such conduct has caused material revenue losses for those venues. The recent resignation of Justice Department Antitrust Chief Abigail Slater was also mentioned in coverage as a factor that may influence the trajectory of the government's case.

On the equities front, UBS has likewise held a Buy rating on Live Nation, with a $164 price target. UBS cited a constructive outlook and what it characterized as a strong finish to the year in Concerts and Sponsorships. UBS also observed that proactive steps in the Ticketing business have temporarily paused adjusted operating income growth, a dynamic that can blunt near-term profitability despite healthier sector momentum elsewhere in the company.

Investors monitoring the name face a mix of operational and legal developments that bear on both near-term earnings and longer-run competitive positioning. Benchmark's Buy reaffirmation emphasizes confidence in attendance trends and venue expansion internationally, while court proceedings and valuation metrics underscore continued downside risk.

Risks

  • Ongoing antitrust litigation and potential DOJ actions - including calls to break up the company or force divestiture of Ticketmaster - create regulatory and operational uncertainty affecting the live events and ticketing sectors.
  • High valuation dynamics - Live Nation trades at a P/E of 112.95 while analysts forecast a drop in net income this year, introducing earnings and market-multiple risk that impacts investor returns.
  • Settlement outcomes and differing stances among federal and state officials - media reports cite possible willingness to settle within some federal quarters but potential resistance from state attorneys general, which could prolong litigation and uncertainty in the music and venue markets.

More from Analyst Ratings

Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026 BWS Financial Boosts A10 Networks Price Target Citing AI-Driven Network Traffic Feb 20, 2026 Supreme Court Ruling Boosts Steve Madden Outlook, Analysts Say Feb 20, 2026